Contattaci Contact Us

12 ottobre 2021 - Giorno 1

  • Introduction

    Relatore Francesco Lanza

    Data Intervento 12/10/2021 - 08:30

  • Genetic landscape of AML and its relevance for treatment

    Relatore Brunangelo Falini

    Data Intervento 12/10/2021 - 08:40

  • DNA repair inhibitors: a possible role in myeloid malignancies

    Relatore Damiano Rondelli

    Data Intervento 12/10/2021 - 09:00

  • Mechanism of resistance

    Relatore Giovanni Martinelli

    Data Intervento 12/10/2021 - 09:20

  • General Discussion Session I

    Relatore -

    Data Intervento 12/10/2021 - 09:40

  • Secondary AML

    Relatore Arnon Nagler

    Data Intervento 12/10/2021 - 10:20

  • Induction and Consolidation Therapy of high risk Leukemia

    Relatore Felicetto Ferrara

    Data Intervento 12/10/2021 - 10:40

  • Allogeneic SCT for High Risk leukemia: when and how

    Relatore Emanuele Angelucci

    Data Intervento 12/10/2021 - 11:00

  • General Discussion Session II

    Relatore -

    Data Intervento 12/10/2021 - 11:20

  • Targeting Apoptosis in AML - venetoclax

    Relatore Dietger Niederwisier

    Data Intervento 12/10/2021 - 13:00

  • Midostaurine and new FLT3 inhibitors

    Relatore Giovanni Marconi

    Data Intervento 12/10/2021 - 13:20

  • IDH1 and IDH2 inhibitors

    Relatore Jorge Cortés

    Data Intervento 12/10/2021 - 13:40

  • Car-T

    Relatore Bipin Savani

    Data Intervento 12/10/2021 - 14:00

  • Strategy to overcome resistance of emerging agents

    Relatore Tapan M. Kadia

    Data Intervento 12/10/2021 - 14:20

  • Targeting MDM2 as a new treatment approach in AML

    Relatore Tapan M. Kadia

    Data Intervento 12/10/2021 - 15:00

  • Bispecific antibody construct for the treatment of AML

    Relatore Marion Subklewe

    Data Intervento 12/10/2021 - 15:40

  • Hedgehog inhibitors

    Relatore Adriano Venditti

    Data Intervento 12/10/2021 - 16:00

  • Immune based approaches in AML

    Relatore Naval Daver

    Data Intervento 12/10/2021 - 16:20

  • General Discussion Session IV

    Relatore -

    Data Intervento 12/10/2021 - 16:40

  • Clinical impact of MRD monitoring

    Relatore Nigel Russell

    Data Intervento 12/10/2021 - 17:20

  • Flow cytometry monitoring

    Relatore Francesco Buccisano

    Data Intervento 12/10/2021 - 17:40

  • MRD by NGS

    Relatore Peter J. M. Valk

    Data Intervento 12/10/2021 - 18:00

  • General Discussion Session V

    Relatore -

    Data Intervento 12/10/2021 - 18:40

13 ottobre 2021 - Giorno 2

  • Mast cell leukemia

    Relatore Michela Rondoni

    Data Intervento 13/10/2021 - 09:00

  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

    Relatore Livio Pagano

    Data Intervento 13/10/2021 - 09:20

  • General Discussion Session VI

    Relatore -

    Data Intervento 13/10/2021 - 09:40

  • High-end GENome-editing platform to deliver next generation allogeneic iPSC-derived CAR-NK and T immunotherapy “GENiCAR”

    Relatore Alejandro Madrigal

    Data Intervento 13/10/2021 - 10:00

  • Intersecting genomic medicine and system pharmacology for profiling therapeutic sensitivity in leukemia

    Relatore Giovanni Roti

    Data Intervento 13/10/2021 - 10:20

  • Haploidentical transplantation in AML

    Relatore Marcos J. De Lima

    Data Intervento 13/10/2021 - 10:40

  • General Discussion Session VII

    Relatore -

    Data Intervento 13/10/2021 - 11:00

  • Ph+ leukemia: biology and resistance

    Relatore Simona Soverini

    Data Intervento 13/10/2021 - 11:40

  • Treatment of Ph+ALL in young and elderly

    Relatore Alessandro Rambaldi

    Data Intervento 13/10/2021 - 12:00

  • Transplant in Ph+

    Relatore Sebastian Giebel

    Data Intervento 13/10/2021 - 12:20

  • General Discussion Session VIII

    Relatore -

    Data Intervento 13/10/2021 - 12:40

  • Transplant in Ph-

    Relatore Alexandros Spdyridonidis

    Data Intervento 13/10/2021 - 14:00

  • First line therapy and overall approach

    Relatore Elias J. Jabbour

    Data Intervento 13/10/2021 - 14:20

  • Role of immunotherapy in refractory-resistant ALL

    Relatore Francesco Lanza

    Data Intervento 13/10/2021 - 14:40

  • Ph Like leukemia

    Relatore Ilaria Iacobucci

    Data Intervento 13/10/2021 - 15:00

  • General Discussion Session IX

    Relatore -

    Data Intervento 13/10/2021 - 15:20

  • Conclusion of the Symposium

    Relatore Francesco Lanza

    Data Intervento 13/10/2021 - 15:40

Area riservata

APP FONDAZIONE MENARINI



Pills of Art Menarini

“Menarini Pills of Art”
Il nuovo progetto multimediale di Menarini legato al mondo dell’arte



Nuovi Progetti: MINUTI DIGITALE



Minuti Menarini Online

Abbonati gratis alla rivista cartacea



Fondazione Internazionale Menarini



ISCRIVITI ALLA NEWSLETTER

Ricevi ogni mese le informazioni sulle attività della Fondazione Internazionale Menarini.

VGFM DATA-LAYER

Fondazione Internazionale Menarini
Fondazione Menarini, Centro Direzionale Milanofiori 20089 Rozzano (MI) - Edificio L - Strada 6
Tel. +39 02 55308110 Fax +39 02 55305739 C.F. 94265730484